Improving the therapeutic monitoring of cyclosporin A

Clinical Transplantation

Volumn 13, Issue 2, 1999, Pages 193-200

  Warrens, A N ^a   Waters, J B ^a   Salama, A D ^a   Lechler, R I ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Cyclosporin A; Kidney transplantation; Therapeutic drug monitoring

Indexed keywords

CYCLOSPORIN A;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; HUMAN; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MICROEMULSION; PRIORITY JOURNAL; TREMOR;

EID: 0032891326     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.1999.130207.x     Document Type: Article

References (33)

1. STILLER C. An overview of the first decade of cyclosporine. Transplant Proc 1996; 28: 2005.
2. FATHMAN C, MYERS B. Cyclosporine therapy for autoimmune disease. New Engl Med 1992; 326: 1693.
3. WITCUP S, SALVO E JR, NUSSENBLATT R. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet's disease. Am J Ophthalmol 1994; 118: 39.
4. DE SMET M, NUSSENBLATT R. Clinical use of cyclosporine in ocular disease. Intl Ophthalmol Clinics 1993; 33: 31.
5. KOO J. Cyclosporine in dermatology. Arch Dermatol 1995; 131: 842.
6. MEYRIER A. Use of cyclosporin in the treatment of idiopathic nephrotic syndrome in adults. Contrib Nephrol 1995; 114: 28.
7. FORRE O. Cyclosporine in rheumatoid arthritis: an overview. Clin Rheumatol 1995; 14 (S2): 33.
8. HELDERMAN J, VAN BUREN D, AMEND W JR, PIRSCH J. Chronic immunosuppression of the renal transplant patient. J Am Soc Nephrol 1994; 4: 2.
9. BARONE G et al. The safety and tolerability of cyclosporine emulsion versus cyclosporine in a randomized, double-blind comparison in primary renal allograft recipients. Transplantation 1996; 61: 968.
10. BARONE G et al. The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. Transplantation 1996; 61: 875.
11. KAHAN B et al. Reduced inter- and intrasubject variability in cyclosporine pharmocokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 1995; 59: 505.
12. WAHLBERG J et al. Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period. Transplantation 1995; 60: 648.
13. CHAPMAN J, O'CONNELL P, BOVINGTON K, ALLEN R. Conversion from Sandimmune to Neoral in stable renal and pancreas transplant recipients enhances cyclosporine absorption. Transplant Proc 1996; 28: 2293.
14. HOPPU K, JALANKO H, LAINE J, HOLMBERG C. Comparison of conventional oral cyclosporine and cyclosporine microemulsion formulations in children with a liver transplant. Transplantation 1996; 62: 66.
15. DALRYMPLE-HAY M et al. Changing stable heart transplant recipients from Sandimmune to Neoral. Transplant Proc 1996; 28: 2285.
16. PETHIG K, RUHPARWAR A, KORN A, CHRISTIANS U, WAHLERS T. Conversion from Sandimmune to Neoral in stable heart transplant recipients. Transplant Proc 1996; 28: 2287.
17. COCKCROFT D, GAULT M. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 13.
18. KAHAN B, GREVEL J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 1988; 46: 631.
19. KAHAN B, WELSH M, RUTZKY L. Challenges in cyclosporine therapy: the role of therapeutic monitoring by area under the curve monitoring. Ther Drug Monitor 1995; 17: 621.
20. BOWLES M, WATERS J, LECHLER R, WILLIAMS G. Do cyclosporin profiles provide useful information in the management of renal transplant recipients? Nephrol Dial Transplant 1996; 11: 1597.
21. LEE S, YANG W, LOONG C, KING L, LIN K. Individualization of cyclosporine therapy in renal transplantation. Transplant Proc 1994; 26: 1917.
22. WOO J. Therapeutic monitoring of cyclosporine. Ann Clin Lab Sci 1994; 24: 60.
23. KOVARIK J et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation - a multicenter investigation in kidney transplant patients. Transplantation 1994; 58: 658.
24. MOORE R. UK multicentre study to assess the safety and tolerability of Neoral in stable renal transplant patients. Transplant Proc 1996; 28: 2202.
25. NEUMAYER H et al. Long-term results of conversion from existing to microemulsion formulation of cyclosporine. Transplant Proc 1996; 28: 2207.
26. MEYER M, BENNETT W, UDEAJAH J, MUNAR M. Evaluation of the efficacy of area under the curve (AUC) cyclosporine (CSA) monitoring [abstract]. J Am Soc Nephrol 1991; 2: 808.
27. SERINO F, CITTERIO F, POZZETTO U, GREVEL J, CASTAGNETO M. Abbreviated three-point kinetic profile in the 12-hour area under the curve for pharmacokinetic monitoring of cyclosporine. Transplant Proc 1994; 26: 2807.
28. JOHNSON A et al. A limited sampling strategy for the measurement of cyclosporine AUC. Transplant Proc 1990; 22: 1345.
29. GREVEL J, KAHAN B. Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Clin Chem 1991; 37: 1905.
30. REGAZZI M, RONDANELLI R, GASTALDI L, MARTINELLI L, VIGANO M. Optimization of sampling time for cyclosporine monitoring in transplant patients. J Clin Pharmacol 1992; 32: 978.
31. GASPARI F, RUGGENENTI P, TORRE L, BERTOCCHI C, REMUZZI G, PERICO N. Failure to predict cyclosporine area under the curve using a limited sampling strategy. Kidney Intl 1993; 44: 436.
32. AMANTE A, KAHAN B. Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate post-transplant period. Transplant Proc 1996; 28: 2162.
33. COONEY G, LUM B, MELIGENI J, DUNN S. Pharmacokinetics of a microemulsion formulation of cyclosporine in pediatric liver transplant recipients. Transplant Proc 1996; 28: 2270.